McKesson (NYSE:MCK) EVP Sells $630,000.00 in Stock

McKesson Corporation (NYSE:MCK) EVP Francisco Fraga sold 600 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $1,050.00, for a total value of $630,000.00. Following the completion of the transaction, the executive vice president owned 5,064 shares in the company, valued at approximately $5,317,200. This represents a 10.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Francisco Fraga also recently made the following trade(s):

• On Thursday, November 5th, Francisco Fraga sold 650 shares of McKesson stock. The stock was sold at an average price of $1,102.96, for a total value of $716,924.00.
• On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The stock was sold at an average price of $995.80, for a total value of $796,640.00.

McKesson Trading Down 1.0%

McKesson stock opened at $1,060.79 on Friday. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,121.50. The company has a market cap of $122.48 billion, a PE ratio of 27.28, a PEG ratio of 2.08 and a beta of 0.27. The company’s 50-day moving average is $938.13 and its two-hundred day moving average is $868.12.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 202.94%. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. During the same quarter last year, the firm earned $9.86 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Research analysts forecast that McKesson Corporation will post 46.21 EPS for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 9.67%.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mawer Investment Management Ltd. lifted its position in shares of McKesson by 5.7% in the third quarter. Mawer Investment Management Ltd. now owns 190,817 shares of the company’s stock worth $162,921,000 after purchasing an additional 10,368 shares in the last quarter. Cornerstone Advisory LLC grew its position in McKesson by 7.0% in the third quarter. Cornerstone Advisory LLC now owns 367 shares of the company’s stock valued at $313,000 after purchasing an additional 24 shares in the last quarter. BankPlus Trust Department increased its stake in McKesson by 72.1% in the 3rd quarter. BankPlus Trust Department now owns 1,805 shares of the company’s stock valued at $1,541,000 after buying an additional 756 shares during the last quarter. Aberdeen Group plc increased its stake in McKesson by 143.4% in the 3rd quarter. Aberdeen Group plc now owns 296,426 shares of the company’s stock valued at $253,091,000 after buying an additional 174,642 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its position in McKesson by 3.9% during the 3rd quarter. Moors & Cabot Inc. now owns 3,081 shares of the company’s stock worth $2,631,000 after buying an additional 115 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Analysts Set New Price Targets

MCK has been the subject of several recent research reports. Leerink Partners upped their target price on shares of McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group raised their price target on McKesson from $1,200.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday. Evercore reaffirmed an “outperform” rating and set a $950.00 price objective (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Robert W. Baird set a $1,015.00 price objective on McKesson in a report on Thursday, August 6th. Finally, Argus upped their price objective on McKesson from $850.00 to $970.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.